In vitro-in vivo correlation of the inhibition potency of sodium-glucose cotransporter inhibitors in rat: A pharmacokinetic and pharmacodynamic modeling approach

Journal of Pharmacology and Experimental Therapeutics

Volumn 345, Issue 1, 2013, Pages 52-61

  Yamaguchi, Koji ^a   Kato, Motohiro ^a   Suzuki, Masayuki ^a   Hagita, Hitoshi ^b   Takada, Maiko ^a   Ayabe, Miho ^a   Aso, Yoshinori ^a   Ishigai, Masaki ^a   Ikeda, Sachiya ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^b Chugai Research Institute for Medical Science Inc   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 (5 BENZOFURANYL) 1 [2 HYDROXY 6 [6 O (METHOXYCARBONYL) BETA DEXTRO GLUCOPYRANOSYL] 4 METHYLPHENYL] 1 PROPANONE; 3 (BENZO[B]FURAN 5 YL) 2',6' DIHYDROXY 4' METHYLPROPIOPHENONE 2' O (6 O METHOXYCARBONYL) BETA DEXTRO GLUCOPYRANOSIDE; 3 (BENZO[B]FURAN 5 YL) 2',6' DIHYDROXY 4' METHYLPROPIOPHENONE 2' O BETA DEXTRO GLUCOPYRANOSIDE; PROTEIN INHIBITOR; SERGLIFLOZIN A; SERGLIFLOZIN ETABONATE; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; T 1095A; TOFOGLIFLOZIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME INHIBITION; GLOMERULUS FILTRATION RATE; GLUCOSE ABSORPTION; GLUCOSE TRANSPORT; GLUCOSE URINE LEVEL; HUMIDITY; IC 50; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FUNCTION; LIQUID CHROMATOGRAPHY; MALE; MATHEMATICAL MODEL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHARMACODYNAMICS; PLASMID; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN TRANSPORT; RADIOACTIVITY; RAT; TANDEM MASS SPECTROMETRY;

ANIMALS; BIOLOGICAL TRANSPORT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSE; HYPOGLYCEMIC AGENTS; KIDNEY TUBULES, PROXIMAL; MALE; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; SODIUM-GLUCOSE TRANSPORTER 1; SODIUM-GLUCOSE TRANSPORTER 2; TANDEM MASS SPECTROMETRY;

EID: 84875447468     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.203125     Document Type: Article

References (36)

1. Abdul-Ghani MA, Norton L, and Defronzo RA (2011) Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev 32:515-531.
2. Chasis H, Jolliffe N, and Smith HW (1933) The action of phlorizin on the excretion of glucose, xylose, sucrose, creatinine and urea by man. J Clin Invest 12:1083-1090.
3. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
4. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095.
5. Deshpande PP, Singh J, Pullockaran A, Kissick T, Ellsworth BA, Gougoutas JZ, Dimarco J, Fakes M, Reyes M, and Lai C, et al. (2012) A practical stereoselective synthesis and novel cocrystallizations of an amphiphatic SGLT-2 inhibitor. Org Process Res Dev 16:577-585.
6. Ellsworth B, Washburn WN, Sher, PM, Wu G, Meng W (2001) inventors, Bristol-Myers Squib, assignee. Preparation of C-aryl glucoside SGLT-2 inhibitors. PCT Int Appl: WO 2001027128 A1 20010419.
7. Elsas LJ and Rosenberg LE (1969) Familial renal glycosuria: a genetic reappraisal of hexose transport by kidney and intestine. J Clin Invest 48:1845-1854.
8. Fujimori Y, Katsuno K, Ojima K, Nakashima I, Nakano S, Ishikawa-Takemura Y, Kusama H, and Isaji M (2009) Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats. Eur J Pharmacol 609: 148-154.
9. Hediger MA and Rhoads DB (1994) Molecular physiology of sodium-glucose cotransporters. Physiol Rev 74:993-1026.
10. Gorboulev V, Schürmann A, Vallon V, Kipp H, Jaschke A, Klessen D, Friedrich A, Scherneck S, Rieg T, and Cunard R, et al. (2012) Na(1)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes 61:187-196.
11. Hummel CS, Lu C, Loo DD, Hirayama BA, Voss AA, and Wright EM (2011) Glucose transport by human renal Na1/D-glucose cotransporters SGLT1 and SGLT2. Am J Physiol Cell Physiol 300:C14-C21.
12. Hussey EK, Dobbins RL, Stoltz RR, Stockman NL, O'Connor-Semmes RL, Kapur A, Murray SC, Layko D, and Nunez DJ (2010) Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: a randomized double-blind study. J Clin Pharmacol 50:636-646.
13. Jabbour SA and Goldstein BJ (2008) Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Int J Clin Pract 62:1279-1284.
14. Jurczak MJ, Lee HY, Birkenfeld AL, Jornayvaz FR, Frederick DW, Pongratz RL, Zhao X, Moeckel GW, Samuel VT, and Whaley JM, et al. (2011) SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes 60:890-898.
15. Katsuno K, Fujimori Y, Takemura Y, Hiratochi M, Itoh F, Komatsu Y, Fujikura H, and Isaji M (2007) Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther 320: 323-330.
16. Kipnes MS (2011) Sodium-glucose cotransporter 2 inhibitors in the treatment of type 2 diabetes: a review of phase II and III trials. Clin Investig 1:145-156.
17. Komoroski B, Vachharajani N, Boulton D, Kornhauser D, Geraldes M, Li L, and Pfister M (2009) Dapagliflozin, a novel SGLT2 inhibitor, induces dosedependent glucosuria in healthy subjects. Clin Pharmacol Ther 85:520-526.
18. List JF and Whaley JM (2011) Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans. Kidney Int Suppl 79: S20-S27.
19. Liu JJ, Lee TW, and DeFronzo RA (2012) Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? Diabetes 61:2199-2204.
20. Magen D, Sprecher E, Zelikovic I, and Skorecki K (2005) A novel missense mutation in SLC5A2 encoding SGLT2 underlies autosomal-recessive renal glucosuria and aminoaciduria. Kidney Int 67:34-41.
21. Maurer TS, Ghosh A, Haddish-Berhane N, Sawant-Basak A, Boustany-Kari CM, She L, Leininger MT, Zhu T, Tugnait M, and Yang X, et al. (2011) Pharmacodynamic model of sodium-glucose transporter 2 (SGLT2) inhibition: implications for quantitative translational pharmacology. AAPS J 13:576-584.
22. Musso G, Gambino R, Cassader M, and Pagano G (2012) A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med 44: 375-393.
23. Nagata T, Fukazawa M, Honda K, Yata T, Kawai M, Yamane M, Murao N, Yamaguchi K, Kato M, and Mitsui T, et al. (2012) Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo-or euglycemic conditions in rats. Am J Physiol Endocrinol Metab [Epub ahead of print].
24. Ohtake Y, Sato T, Kobayashi T, Nishimoto M, Taka N, Takano K, Yamamoto K, Ohmori M, Yamaguchi M, and Takami K, et al. (2012) Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 55:7828-7840.
25. Oku A, Ueta K, Arakawa K, Ishihara T, Nawano M, Kuronuma Y, Matsumoto M, Saito A, Tsujihara K, and Anai M, et al. (1999) T-1095, an inhibitor of renal Na1-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 48:1794-1800.
26. +)-glucose cotransporter, in neonatally streptozotocin-treated rats. Eur J Pharmacol 391:183-192.
27. Oulianova N and Berteloot A (1996) Sugar transport heterogeneity in the kidney: two independent transporters or different transport modes through an oligomeric Protein? 1. Glucose transport studies. J Membr Biol 153:181-194.
28. Rossetti L, Smith D, Shulman GI, Papachristou D, and DeFronzo RA (1987) Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 79:1510-1515.
29. Silverman M, Aganon MA, and Chinard FP (1970) D-glucose interactions with renal tubule cell surfaces. Am J Physiol 218:735-742.
30. Suzuki M, Honda K, Fukazawa M, Ozawa K, Hagita H, Kawai T, Takeda M, Yata T, Kawai M, and Fukuzawa T, et al. (2012) Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther 341:692-701.
31. Turner RJ and Moran A (1982) Heterogeneity of sodium-dependent D-glucose transport sites along the proximal tubule: evidence from vesicle studies. Am J Physiol 242:F406-F414.
32. Vallon V, Platt KA, Cunard R, Schroth J, Whaley J, Thomson SC, Koepsell H, and Rieg T (2011) SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 22:104-112.
33. Wright EM (2001) Renal Na(1)-glucose cotransporters. Am J Physiol Renal Physiol 280:F10-F18.
34. Yamaguchi K, Kato M, Suzuki M, Asanuma K, Aso Y, Ikeda S, and Ishigai M (2011) Pharmacokinetic and pharmacodynamic modeling of the effect of an sodiumglucose cotransporter inhibitor, phlorizin, on renal glucose transport in rats. Drug Metab Dispos 39:1801-1807.
35. Yamaguchi K, Kato M, Ozawa K, Kawai T, Yata T, Aso Y, Ishigai M, and Ikeda S (2012) Pharmacokinetic and pharmacodynamic modeling for the effect of sodiumglucose cotransporter inhibitors on blood glucose level and renal glucose excretion in db/db mice. J Pharm Sci 101:4347-4356.
36. Yamaoka K, Tanigawara Y, Nakagawa T, and Uno T (1981) A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobiodyn 4:879-885.